WO2016005564A3 - Antibodies against activated factor v - Google Patents

Antibodies against activated factor v Download PDF

Info

Publication number
WO2016005564A3
WO2016005564A3 PCT/EP2015/065848 EP2015065848W WO2016005564A3 WO 2016005564 A3 WO2016005564 A3 WO 2016005564A3 EP 2015065848 W EP2015065848 W EP 2015065848W WO 2016005564 A3 WO2016005564 A3 WO 2016005564A3
Authority
WO
WIPO (PCT)
Prior art keywords
activated factor
antibodies against
against activated
factor
fva
Prior art date
Application number
PCT/EP2015/065848
Other languages
French (fr)
Other versions
WO2016005564A2 (en
Inventor
Heidi Lindgreen Holmberg
Gustav RØDER
Kristoffer Winther BALLING
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of WO2016005564A2 publication Critical patent/WO2016005564A2/en
Publication of WO2016005564A3 publication Critical patent/WO2016005564A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to monoclonal antibodies or fragments thereof, that bind to activated Factor V (FVa), that display pro-coagulant effect and therapeutic uses in thereof.
PCT/EP2015/065848 2014-07-11 2015-07-10 Antibodies against activated factor v WO2016005564A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14176717.8 2014-07-11
EP14176717 2014-07-11

Publications (2)

Publication Number Publication Date
WO2016005564A2 WO2016005564A2 (en) 2016-01-14
WO2016005564A3 true WO2016005564A3 (en) 2016-04-07

Family

ID=51162604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/065848 WO2016005564A2 (en) 2014-07-11 2015-07-10 Antibodies against activated factor v

Country Status (3)

Country Link
AR (1) AR101185A1 (en)
TW (1) TW201617371A (en)
WO (1) WO2016005564A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018346681B2 (en) * 2017-10-05 2024-02-22 Epivax, Inc. Regulatory T cell epitopes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910576A (en) * 1994-02-14 1999-06-08 Rijks Universiteit Leiden Method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein
WO2005111075A2 (en) * 2004-05-18 2005-11-24 University Of Vermont And State Agricultural College CRYSTAL STRUCTURE OF FACTOR VAi AND METHOD FOR IDENTIFYING BLOOD FACTOR Va MODULATORS
WO2007101106A2 (en) * 2006-02-23 2007-09-07 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis using variant forms of activated factor v
WO2008067056A2 (en) * 2006-10-16 2008-06-05 Novelmed Therapeutics, Inc. Method of inhibiting coagulation with human anti-factor va antibodies and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910576A (en) * 1994-02-14 1999-06-08 Rijks Universiteit Leiden Method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein
WO2005111075A2 (en) * 2004-05-18 2005-11-24 University Of Vermont And State Agricultural College CRYSTAL STRUCTURE OF FACTOR VAi AND METHOD FOR IDENTIFYING BLOOD FACTOR Va MODULATORS
WO2007101106A2 (en) * 2006-02-23 2007-09-07 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis using variant forms of activated factor v
WO2008067056A2 (en) * 2006-10-16 2008-06-05 Novelmed Therapeutics, Inc. Method of inhibiting coagulation with human anti-factor va antibodies and use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANNETTE VON DRYGALSKI ET AL: "Superior in Vivo Hemostatic Properties of an Engineered Factor Va Variant for Hemophilia Mice", vol. 120, no. 21, 1 November 2012 (2012-11-01), XP002722413, ISSN: 0006-4971, Retrieved from the Internet <URL:https://ash.confex.com/ash/2012/webprogram/Paper50002.html> [retrieved on 20150917] *
KALAFATIS M ET AL: "Contribution of the heavy and light chains of factor Va to the interaction with factor Xa", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 33, no. 21, 31 May 1994 (1994-05-31), pages 6538 - 6545, XP002590638, ISSN: 0006-2960 *
KENNETH SEGERS ET AL: "Coagulation factor V and thrombophilia: Background and mechanisms", THROMBOSIS AND HAEMOSTASIS, vol. 98, no. 3, 17 October 2007 (2007-10-17), pages 530 - 42, XP055175994, ISSN: 0340-6245, DOI: 10.1160/TH07-02-0150 *
SCHLACHTERMAN A ET AL: "Factor V Leiden improves in vivo hemostasis in murine hemophilia models", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, vol. 3, no. 12, 1 December 2005 (2005-12-01), pages 2730 - 2737, XP008130621, ISSN: 1538-7933, DOI: 10.1111/J.1538-7836.2005.01639.X *
SUHNG WOOK KIM ET AL: "Identification of Functionally Important Amino Acid Residues within the C2-Domain of Human Factor V Using Alanine-Scanning Mutagenesis +", BIOCHEMISTRY, vol. 39, no. 8, 1 February 2000 (2000-02-01), pages 1951 - 1958, XP055171137, ISSN: 0006-2960, DOI: 10.1021/bi992256r *
W B FOSTER ET AL: "Monoclonal Antibodies Selective for Activated Factor V", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 258, no. 9, 10 March 1983 (1983-03-10), pages 5606 - 5613, XP055177012, Retrieved from the Internet <URL:http://www.jbc.org/content/258/9/5608.full.pdf> [retrieved on 20150316] *

Also Published As

Publication number Publication date
TW201617371A (en) 2016-05-16
WO2016005564A2 (en) 2016-01-14
AR101185A1 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
PH12017502180A1 (en) Tau-binding antibodies
WO2015112886A3 (en) Binding proteins and methods of use thereof
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
MX2022004072A (en) Factor xi antibodies and methods of use.
WO2016191643A3 (en) Tigit-binding agents and uses thereof
MX2020010530A (en) Humanized antibodies against cd269 (bcma).
EA201791485A1 (en) ANTI-CD47-ANTIBODIES AND THEIR APPLICATIONS
MX2017011281A (en) Amatoxin-antibody conjugates.
WO2015197823A3 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EP3176181A4 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
WO2016014974A3 (en) Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
PH12017502207A1 (en) Tau-binding antibodies
WO2016054598A3 (en) Antibodies that bind ebola glycoprotein and uses thereof
WO2016004389A3 (en) Monovalent binding proteins
EP3353213A4 (en) Novel anti-mesothelin antibody and composition comprising the same
SG10201909716RA (en) Modified j-chain
WO2016055432A3 (en) Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
WO2014163714A3 (en) Antibody drug conjugates
WO2015075269A9 (en) Antibodies against ccr9 and applications thereof
WO2017019957A3 (en) Binding proteins and methods of use thereof
MX2017007747A (en) Antibodies for il-17c.
WO2017044866A3 (en) Enhanced delivery of drugs to the brain
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
EP3150632A3 (en) Anti-ricin antibodies and uses thereof
WO2016005564A3 (en) Antibodies against activated factor v

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15736498

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15736498

Country of ref document: EP

Kind code of ref document: A2